Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY: BMY )

69.31 +1.11 (+1.63%)
Official Closing Price Updated: 4:10 PM EDT, Mar 31, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
34 35 Next >
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Bristol-Myers Squibb Company and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
Bristol Myers Q3 Earnings In-line With Expectations, Raises Lower End Of FY21 Adjusted EPS Outlook
Bristol Myers Squibb & Co (NYSE: BMY) has posted Q3 revenues of $11.6 billion, an increase of 10%, in line with the consensus estimate of $11.58 billion. ... 
Via Benzinga
Bristol Myers Inches Up As Cancer Drugs Help Drive Narrow Quarterly Beat
Bristol Myers credited cancer drugs Opdivo and Revlimid for helping drive its growth. 
Via Investor's Business Daily
Bristol Myers Squibb Reports Third Quarter Financial Results for 2021
From Bristol Myers Squibb
Via Business Wire
BRISTOL-MYERS CVR INVESTORS: December 6, 2021 Filing Deadline in Class Action – Contact Lieff Cabraser
From Lieff Cabraser Heimann & Bernstein, LLP
Via Business Wire
Cyber Currency
Canadian stocks are particularly buoyant and not just in energy which is a riser today because the loony is up against the buck. 
Via Talk Markets
Aurinia Rockets — Again — On Rumored Bristol Marriage; Could Others Make A Pass?
Aurinia stock hit another record Monday on Bristol's rumored takeover. 
Via Investor's Business Daily
Bristol Myers Squibb Announces Earnings Call Time Change; Third Quarter 2021 Earnings Call to Occur on October 27, 2021 at 10 a.m. (Eastern Time)
From Bristol Myers Squibb
Via Business Wire
The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More
Biotech stocks posted gains for the second week running, supported by multiple catalysts that included a good start to the big pharma reporting season and broader market strength... 
Via Benzinga
Exposures Product Safety
Why Aurinia Pharmaceuticals Stock Is Blasting Higher Today
The biotech is reportedly in buyout talks with Bristol Myers Squibb. 
Via The Motley Fool
Aurinia Pharma Stock Pops On Reports Of Looming Bristol Myers Takeover
Bristol is reportedly interested in acquiring Aurinia, according to reports that sent AUPH stock flying before it was halted. 
Via Investor's Business Daily
The Bristol Myers Squibb Foundation Diversity in Clinical Trials Career Development Program Announces First Group of Physicians to Be Trained
SOURCE: Bristol Myers Squibb Company 
Via 3BL Media
Thursday Market Coverage
US jobless benefit applicants last week hit a pandemic low of 290,000, below the estimate of 300,000. 
Via Talk Markets
Clorox and Church & Dwight versus Amgen and Bristol-Myers Squibb
Base your stock investment decisions on fundamental values rather than short-term price activity. 
Via Talk Markets
Ventyx Jumps Over 20% Today After NASDAQ Debut
Less than a year ago, Ventyx Biosciences Inc (NASDAQ: VTYX) emerged from stealth mode, then last month, it sprinted to Wall Street with a $100 million IPO ticket. This... 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
Bristol Myers Pledges To Offload Acceleron Shares: Bloomberg
Bristol-Myers Squibb Co (NYSE: BMY) is planning to tender its shares in Acceleron Pharma Inc (NASDAQ: XLRN) after Merck & Co Inc (NYSE: MRK) agreed... 
Via Benzinga
The Daily Biotech Pulse: FDA Authorizes Moderna, J&J Booster Shots; Regulatory Approvals For Bristol-Myers Squibb, Sanofi-Regeneron; Ventyx IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus CDC Committee Recommends Approval Of Merck, Pfizer's Pneumococcal Vaccine... 
Via Benzinga
Exposures Product Safety
Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) + Chemotherapy for Patients with HER2 Negative, Advanced or Metastatic Gastric, Gastroesophageal Junction or Esophageal Adenocarcinoma …
From Bristol Myers Squibb
Via Business Wire
Wednesday Market Coverage
Today gold rose again despite the active market for bitcoin and the lower Chinese demand for mine products like iron and coal. 
Via Talk Markets
The Bristol Myers Squibb Foundation Diversity in Clinical Trials Career Development Program Announces First Group of Physicians to be Trained
From Bristol Myers Squibb
Via Business Wire
The Secret To Successful Investing In Biotech
Have you ever had a stock jump 30%, 50% or 100% in one day? 
Via Talk Markets
The Daily Biotech Pulse: Entasis, Dermata Spike Higher On Positive Readouts, J&J Q3 EPS Beats Estimates, Wave Life Sciences Regains Right To CNS Portfolio
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Entasis Announces Positive Data For Late-Stage Study Of SUL-DUR In... 
Via Benzinga
Celebrating the Science That Transforms Patients' Lives
SOURCE: Bristol Myers Squibb Company 
Via 3BL Media
Week In Review: Hansoh Signs $456 Million Deal For siRNA Products
Hansoh Pharma of Shanghai announced a $456 million agreement to develop siRNA products in Greater China from South Korea's OliX Pharma. Hansoh will make an upfront payment of $6.5 million and up to... 
Via Talk Markets
Europe's Unicorns
After markets jumped yesterday, we saw a lot of bounce today although gold fell back a bit. 
Via Talk Markets
Bristol Myers Squibb Receives Positive CHMP Opinion for Zeposia (ozanimod) as a Treatment for Adult Patients with Moderately to Severely Active Ulcerative Colitis
From Bristol Myers Squibb
Via Business Wire
This Company Revolutionizes What Matters for Hospitals, Big Pharma and Health Insurers
You can perch on a 1-legged stool and balance precariously on 2, but if you want to settle in with comfort and safety, you need 3 sturdy legs. With its secure, cloud-based... 
Via Benzinga
Team BMS Moves for Minutes to Benefit Special Olympics
SOURCE: Bristol Myers Squibb Company 
Via 3BL Media
Exposures COVID-19
Bristol Myers Squibb Announces Up to Five Years of Data from Long-Term DAYBREAK Study Reinforcing Efficacy and Safety Profile of Zeposia (ozanimod) in Patients with Relapsing Forms of Multiple Sclerosis
From Bristol Myers Squibb
Via Business Wire
Death Cross Looms Over Bristol-Myers Squibb Investors
If history is any guide, there may be trouble ahead for shares of Bristol-Myers Squibb(NYSE:BMY). A so-called "death cross" has formed on its chart and, not surprisingly, this... 
Via Benzinga
< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
34 35 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.